tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Altimmune resumed with a Sell at Goldman Sachs

Goldman Sachs resumed coverage of Altimmune (ALT) with a Sell rating and $1 price target representing 79% downside. The company’s data to-date has not demonstrated a meaningfully differentiated profile for pemvidutide in either obesity or metabolic dysfunction associated steatohepatitis, the analyst tells investors in a research note. The firm sees challenges for Altimmune to execute the full clinical development program required to bring pemvidutide to market.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1